Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.
Advanced Unresectable Solid Tumors
DRUG: M108|DRUG: M108
Incidence of adverse events, defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0), From enrollment until 28+7 days after the last dose|Maximum Tolerated Dose, MTD, 21 days
Maximum measured plasma concentration of M108, Cmax, From enrollment until 28 days after the last dose|Time to maximum plasma concentration of M108, Tmax, From enrollment until 28 days after the last dose|Half-life of M108, T1/2, From enrollment until 28 days after the last dose|Immunogenicity profile of M108, Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies(ADA)., From enrollment until 28 days after the last dose|Objective Response Rate, ORR, From first dose to disease progression , death or end of study，an average of 1 year|Progression free survival, PFS, From first dose to disease progression , death or end of study，an average of 1 year
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.